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Resumo 
O desencadeamento da disfunção do metabolismo proteico nas formas 
esporádicas da doença de Parkinson (PD) poderá resultar do stress oxidativo 
mediado por espécies reactivas de oxigénio (ROS). O stress do reticulo 
endoplasmático (ER) pode levar à produção de ROS e ao desequilíbrio redox 
no ER mas a relação exacta entre o stress oxidativo e o stress do ER está 
pouco documentada. No entanto, sabe-se que a produção de ROS por 
neurotoxinas indutoras de parkinsonismo leva a uma rápida acumulação de 
proteínas oxidadas que por sua vez podem activar a unfolded protein response 
(UPR) 
Um potencial mecanismo de defesa celular contra a toxicidade das ROS 
é a indução da expressão de enzimas de destoxificação de Fase II, 
nomeadamente a Glutationa S-Transferase Pi (GSTP), pelo factor de 
transcrição Nrf2. Já demonstrámos que a administração sub-aguda de 1-metil-
4-fenil-1,2,3,6-tetrahidropiridina (MPTP) a ratinhos C57BL/6 induz a expressão 
da GSTP, e que a degeneração e morte de neurónios dopaminérgicos 
causadas pelo MPTP ocorre mais precocemente nos ratinhos knockout para a 
GSTP (GSTP KO) do que nos ratinhos wild type (wt). Para além disso, o nosso 
grupo também demonstrou que o ácido tauroursodeoxicólico (TUDCA), um 
ácido biliar endógeno com propriedades anti-apoptóticas e neuroprotectoras, 
diminui a morte celular em neurónios dopaminérgicos tratados com MPTP. 
Neste estudo, avaliámos os níveis de expressão de marcadores de 
stress do ER no córtex de ratinhos C57/BL6 wt e ratinhos GSTP KO após o 
tratamento com MPTP. Em paralelo, investigámos também o papel do TUDCA 
na redução do stress do ER. 
Os nossos resultados mostram que neste modelo de PD in vivo os 
ratinhos GSTP KO apresentam um decréscimo nos níveis de expressão de 
ATF6α e um aumento nos níveis de expressão de IRE1α quando comparados 
com os ratinho wt. Curiosamente, o efeito mais proeminente da deleção dos 
genes Gstp1/2 foi observado nas amostras de ratinhos tratados com MPTP, 
nas quais os níveis de expressão de Nrf2 se encontram reduzidos de forma 
significativa nos ratinhos GSTP KO quando comparadas com as amostras 
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correspondentes de ratinhos wt. Verificámos também que o pré-tratamento com 
TUDCA modulou os níveis de expressão de diferentes mediadores da UPR 
após o insulto com MPTP. 
Ainda que preliminares, os resultados aqui apresentados mostram que 
no encéfalo de ratinho, diferentes componentes da UPR apresentam diferentes 
susceptibilidades ao stress oxidativo induzido pelo MPTP. Essas diferenças 
estão relacionadas com o genótipo dos ratinhos (wt vs GSTP KO) o que indica 
que a GSTP possa desempenhar um papel na manutenção do equilíbrio redox 
no ER. 
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Abstract 
The trigger for dysfunctional protein metabolism, in sporadic Parkinson’s 
disease (PD), may be oxidative stress through damage caused by reactive 
oxygen species (ROS). The endoplasmic reticulum (ER) stress may trigger 
ROS production and redox imbalance in the ER but the precise interplay 
between oxidative stress and ER stress in neurons has been sparsely 
described. However, generation of ROS by PD triggering neurotoxins leads to a 
rapid accumulation of oxidized proteins that can activate the unfolded protein 
response (UPR). 
One potential defence against the toxicity of ROS is the up-regulation of 
phase II detoxification enzymes, namely Glutathione S-Transferase Pi (GSTP), 
by the Nrf2 transcription factor. We have demonstrated that the sub-acute 
administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to 
C57BL/6 mice induced GSTP expression and that MPTP-induced dopaminergic 
neuronal degeneration is an earlier event when comparing GSTP null vs wild 
type (wt) mice. Furthermore, our group has also shown that 
tauroursodeoxycholic acid (TUDCA), an endogenous bile acid with anti-
apoptotic and neuroprotective properties, rescued dopaminergic neurons from 
MPTP-induced damage.  
In the present study, we evaluated the expression levels of ER stress 
markers in the cortex of C57/BL6 wt mice and GSTP null mice under MPTP-
induced oxidative stress. In parallel, we investigated the role of TUDCA in 
reducing ER stress.  
Our results show that in this in vivo model of PD GSTP null mice exhibit a 
decrease in ATF6α expression levels while exhibiting an increase in IRE1α 
expression levels when compared to the wild type. Interestingly, the most 
prominent effect of Gstp1/2 deletion was observed in the MPTP-treated 
samples, in which Nrf2 expression levels are significantly decreased in GSTP 
null mice when compared to their wt counterparts. We also observed that pre-
treatment with TUDCA modulated the expression levels of the different UPR 
mediators following the MPTP insult. 
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Although preliminary, the results present herein show that in the mice 
brain, different components of the UPR display different susceptibilities to 
MPTP-oxidative stress. These differences relay on the mice genotype (wt vs 
Gstp null) indicating that GSTP may have also a role in maintaining the ER 
redox balance.  
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1. Parkinson’s Disease 
 
 PD is a chronic and progressive neurodegenerative disorder, 
characterized by a large number of motor and non-motor features (Jankovic, 
2008). Firstly identified in 1817 by James Parkinson, it is the second most 
common neurodegenerative disease. Its pathophysiological hallmarks are loss 
or degeneration of dopaminergic neurons in the SN of the midbrain, resulting in 
a decrease of DA levels, and the development of neuronal LB, abnormal 
intracytoplasmic aggregates of protein that mostly contain α-synuclein, as well 
as ubiquitin and phosphorylated neurofilament proteins (Kim et al., 2014). DA is 
a neurotransmitter essential for normal movement, allowing information 
concerning motor control to be transmitted from the SN to the striatum, which 
then initiates and controls the ease and balance of movement (Segura-Aguilar 
et al., 2014).  
 Due to the decrease in DA levels, the symptomatology of PD is 
characterized by four major cardinal motor symptoms: tremor (e.g. hand tremor 
at rest), akinesia or bradykinesia (loss of spontaneous movements, facial 
expression), muscle rigidity and impaired balance and posture (stooping 
posture) (Hindle, 2010). Furthermore, LB can also occur in multiple areas of the 
central and peripheral autonomic nervous system, giving rise to a variety of 
symptoms in addition to the classical PD motor features (Sprenger and Poewe, 
2013). There is a big spectrum of non-motor features that PD patients may 
suffer from, and that may reduce their quality of life, which are not only frequent 
but also often under-reported by patients and caregivers alike, remaining 
consequently under-treated (Maass and Reichmann, 2013). These include 
neurobehavioural disorders like depression, anxiety, apathy, hallucinations, 
cognitive impairment, impulse disorders (binge eating, pathological gambling) 
(Chaudhuri et al., 2011) and sleep disorders like difficulties with falling asleep, 
REM sleep behavior disorder and non-REM parasomnias (confusional 
wandering) (Maas and Reichmann, 2013). Also, PD patients report symptoms 
like constipation, genitourinary urgency, sensory pain and visual diplopia 
(Jellinger 2014). 
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Even though PD symptoms are well characterized, its ultimate causes 
are still unknown. Recent decades have witnessed a proliferation of medical 
pharmacological therapies and innovative surgical interventions like deep brain 
stimulation, but definitive disease modifying therapy is still lacking. 
 
1.1. Epidemiology and risk factors 
 
 It is estimated that approximately 1-2% of the population over 65 years 
suffers from PD, with this figure increasing to 3% to 5% in people 85 years and 
older (Alves et al., 2008). Incidence rates of PD in population-based studies 
from Europe and the USA range from 8.6 to 19 per 100,000 inhabitants. PD can 
be sporadic, which comprises the majority of cases, or familial PD, in which 
patients with the disease report a positive family history. Indeed the highest risk 
factor for PD is considered to be family history, with monogenic forms, caused 
by single mutation in dominantly or recessively inherited gene, accounting for 
30% of familial PD (Noyce et al., 2012). Other risk factors include pesticide 
exposure (Wilk et al., 2006) and aging. 
There were identified 18 specific chromosomal regions, also called 
chromosomal locus, with a putative link to PD termed PARK (Table 1). 
However, the causative gene has not yet been identified for all of the loci, with 
some of them being identified by genetic linkage analysis in large families, and 
others discovered and established by genome wide association performed on a 
population level (Klein and Westenberger, 2012). Several genes have been 
found to be associated with PD (Table 1), namely SNCA, which encodes for α-
synuclein, the main component of LB, LRRK2, a gene that encodes the 
cytoplasmic protein leucine-rich repeat kinase 2, PARK2, the second largest 
gene in the human genome that encodes for parkin, a protein that functions as 
an E3 ubiquitin ligase in the process of ubiquitination, PINK1, a phosphatase 
and tension homolog-induced putative kinase 1 that functions in a common 
pathway with parkin for sensing and selectively eliminating damaged 
mitochondria from the mitochondrial network, and DJ-1, a protein ubiquitously 
expressed that functions as a cellular sensor of oxidative stress (Klein and 
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Westenberger, 2012). Each gene has different effects on various aspects of the 
disease, such as the onset of the disease or the severity of the symptoms. 
 
 
 
1.2 Pathophysiology of PD 
 
As previously mentioned, PD is characterized by the degeneration of 
dopaminergic neurons in the SN of the midbrain, which results in a progressive 
nigrostriatal DA deficiency. It also features the presence of proteinaceous 
intracellular bodies containing aggregates of α-synuclein. This protein is 
considered to play a central role in the pathophysiology of PD, as its fibrillar 
form is known to be a major structural component of LBs in PD and other 
synucleinopathies (Kim et al., 2014). Accumulation of α-synuclein at the 
synapse leads to a loss of synaptic proteins and synaptic pruning with loss of 
Table 1 – PARK-designated PD-related loci. Adapted from Klein and Westenberger, 
(2012). 
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connectivity. In vitro studies have shown that α-synuclein aggregates cause a 
series of secondary processes leading to neuroinflammation, 
neurodegeneration and cell death, providing compelling evidence that α-
synuclein is involved in the pathogenesis of PD (Kim et al., 2014). However, it 
seems that the displacement of α-synuclein monomers from their physiological 
location in the cells may also contribute to neurodegeneration (Lashuel et al., 
2013). Furthermore, it is also thought that oxidative damage may play a 
pertinent role in the aggregation of α-synuclein in PD due to a selective tyrosine 
nitration of this protein in lesions in PD and other synucleinopathies (Moore et 
al., 2005). The source of the increased oxidative stress is unclear but may 
include mitochondrial dysfunction, increased DA metabolism that can yield 
excess hydrogen peroxide and other ROS and impaired antioxidant defense 
pathways (Jenner 2003). Oxidative stress is considered to compromise the 
integrity of vulnerable neurons and thus to contribute to neuronal degeneration, 
and its role in PD will be latter discussed. 
 
1.3 Diagnosis and treatment  
 
 Despite decades of research, the diagnosis and subsequent 
management of PD is hampered by suboptimal methods for detection and 
prognosis due to the lack of valid diagnostic biomarkers (tests or screening 
mechanisms) with high sensitivity and specificity that are critically needed for 
the correct identification of the disease. The definite and accurate diagnosis of 
PD can only be done through post-mortem neuropathological examination of 
brain tissue from PD patients. During lifetime, the diagnosis of PD relies on 
clinical criteria, based chiefly in the presence of parkinsonian symptoms. This 
proves to be a challenging task given the fact that the classic PD symptoms can 
be present in other neurodegenerative disorders. Careful history taking and 
astute physical assessment coupled with initial medical therapy are necessary 
to distinguish PD from other diseases or from secondary parkinsonism due to 
provoking drugs, toxins, infections and neurological damage (Beitz 2014). 
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 Although there are no available disease-modifying therapies to alter the 
underlying neurodegenerative process, symptomatic therapies can improve the 
patients’ quality of life. These pharmacological approaches target chiefly the  
nigrostriatal dopaminergic pathway and attempt to replenish the DA content in 
the brain even though they do not prevent the progression of PD. L-DOPA 
remains as the gold standard because it can readily cross the BBB and is 
converted to DA through the  
actions of the enzyme DOPA decarboxylase (Hornykiewicz, 2002). However, L-
DOPA is also converted into DA in the peripheral nervous systems, causing 
undesirable adverse events such as nausea and vomiting. Given these effects, 
it is standard in clinical practice to co-administer L-DOPA with DOPA 
decarboxylase inhibitor such as carbidopa that does not cross the BBB, 
reducing the conversion of L-DOPA to dopamine in the peripheral tissue and 
therefore increasing L-DOPA delivery to the brain (Nagatsua and Sawadab, 
2009). However, long-term L-DOPA treatment is associated with significant 
complications including involuntary movements, dyskinesias and response 
fluctuations (Tarazi et al., 2014).  
Medication should be initiated when patients experience functional 
impairment from their symptoms. Initial therapy selection typically depends on 
patients’ specific symptoms and age. If motor symptoms are mild but require 
therapy, MAO-B inhibitors may be used before moving into more potent 
treatments such as L-DOPA. These inhibitors can increase synaptic dopamine 
by blocking its metabolization and are currently approved for the symptomatic 
treatment of early PD and to reduce off-time in patients with more advanced 
PD, having demonstrated a small symptomatic benefit and potential disease-
modifying effects (Connolly and Lang, 2014). However, these agents have 
limited use in clinical management due to its low efficacy and possible drug 
interactions with medications that are contraindicated when taken with MAO 
inhibitors (Chen, 2011). Several promising new families of drugs are being 
evaluated for treatment of PD, including adenosine A2A receptor antagonists, 
neurotrophic factors, glutamate antagonists and transdermal nicotine (Payami 
and Factor, 2014). However, none of these has been approved for general use  
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and often the reason is insufficient efficacy. In summary, current treatments for 
PD do not provide adequate neuroprotection and have limited efficacy, being 
incapable of slowing the progression of this disease and being associated with 
adverse motor and non-motor side effects. Accordingly, there is an urgent need 
to develop novel pharmacotherapies that are superior to the current ones, with 
improved efficacy, safety and long-term maintenance. 
 
1.4 Models of PD 
 
Currently, there is a plethora of animal models that mimic different 
aspects related to the pathology of PD. All of these experimental models can be 
categorized into two main groups: toxin-induced models and genetic models. 
None of the currently available models copy the phenotype of PD, mainly 
because they lack some specific neuropathological and/or behavioral feature of 
this disease, with each model having certain advantages and shortcomings. In 
addition to the classical motor abnormalities observed in PD, animal models are 
increasingly used to study non-motor symptoms (Campos et al., 2013). Both 
toxin-based and genetic models are suitable for studying these non-motor 
symptoms that are increasingly recognized as relevant in disease-state. 
 
1.4.1. Toxin-induced models of PD 
 
Toxin-based models of parkinsonism have been widely used and have 
yielded a wealth of insight into PD neuropathogenesis while also providing 
disease models in which to define putative pharmacological targets and to test 
potential therapies. These models have continued to evolve and have been 
used to study PD for more than half a century, starting with the 6-OHDA model 
of parkinsonism, introduced in the late 1950’s (Mendez and Finn, 1975). The 
structure of this selective catecholaminergic neurotoxin is very similar to that of 
DA, but an additional hydroxyl group on 6-OHDA renders it specifically toxic to 
dopaminergic neurons. Much of the biochemical, physiological and behavioral 
effects of nigral dopaminergic neuron loss and striatal DA depletion has been  
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collected from the 6-OHDA model of parkinsonism, with oxidative stress being 
widely regarded as the primary mechanism through which this molecule exerts 
its effects (Martinez and Greenamyre, 2012). 
The molecule MPTP was first recognized as a neurotoxin when a group 
of intravenous heroin users developed an acute version of parkinsonism that 
was symptomatically indistinguishable from sporadic PD (Langston et al.,1983). 
MPTP was discovered to be a contaminant in the synthetic heroin that poisoned 
the drug users, and after it was recognized to function as a DA neurotoxicant, 
animal models were quickly developed, initially through repeated injections of 
MPTP in monkeys, providing the first effective non-human primate model of 
parkinsonism (Burns et al, 1983), and paving the way for the widespread use of 
MPTP as an in vivo neurotoxin. This molecule has been shown to be toxic in a 
large range of species and it is the tool of choice for investigations into the 
mechanisms involved in the death of dopaminergic neurons in PD, causing 
damage primarily to the nigrostriatal DA pathway with a profound loss of DA in 
the striatum and SN (Dauer and Przedborski, 2003). MPTP neurotoxicity arises 
from the formation of the toxic MPP+ metabolite, which decreases ATP 
production, inhibits mitochondrial enzymes and increases ROS production 
(Figure 1) (Nicklas et al, 1985). Several studies have demonstrated that JNK, a 
protein that belongs to a family of stress kinases subject to transient activation 
in response to ROS, heat or osmotic shock and growth factors or inflammatory 
cytokines (Davis, 2000), is a key mediator of MPTP/MPP+-induced neuronal 
apoptosis in animal models of PD (Nishi, 1997; Saporito et al., 2000). It has 
been shown that the SN of MPTP-treated mice presents increased levels of 
JNK and c-Jun (Silva et al., 2005; Castro-Caldas et al., 2012), supporting the 
idea that this kinase is somehow involved in the MPTP-induced degeneration of 
dopaminergic neurons. Also, it was shown that JNK null mice are resistant to 
MPTP neurotoxicity (Hunot et al, 2004) and selective inhibitors of JNK protect 
against the neurodegeneration in the nigrostriatal dopaminergic neurons caused 
by MPTP (Saporito et al., 1999; Wang et al., 2004). JNK activation is mediated 
through a sequential kinase cascade that results in the dual phosphorylation of 
the Thr-Pro-Tyr motif located in its activation loop (Davis, 2000), after which  
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JNK phosphorylates c-Jun, increasing its transcriptional activity and leading to 
the up-regulation of a number of genes involved in the control of cell survival 
and apoptosis (Kuan and Burke, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among the toxic animal models of PD, rotenone represents one of the 
most recently used approaches (Betarbet et al., 2000). This substance is widely 
used around the world as an insecticide and pesticide, and it is a member of the 
rotenoids, a family of natural cytotoxic compounds extracted from various parts 
of Leguminosae plants (Hisata, 2002). Similarly to MPTP, rotenone is highly 
lipophilic and thus readily gains access to all organs including the brain. 
Furthermore, this neurotoxin also freely crosses all cellular membranes and can 
accumulate in subcellular organelles such as the mitochondria. After a single 
intravenous injection, rotenone reaches maximal concentration in the central 
nervous system within 15 minutes and decays to about half of this level in less 
Figure 1 – Schematic representation of MPTP metabolism and intracellular 
pathways affected by MPP
+
. Following systemic injection, MPTP readily 
crosses the BBB and is metabolized through the action of MAO-B in glial 
cells, converting MPTP to MPDP
+
, which is then rapidly deprotonated (likely 
due to spontaneous oxidation) to the active neurotoxin MPP
+
 (Przedborski 
et al, 2004). Afterwards, MPP
+ 
is released into the extracellular space where 
it enters dopaminergic neurons through selective uptake by the DA 
transporter. Once inside the neuron, MPP
+
 enters the mitochondria through 
a mechanism dependent of mitochondrial transmembrane potential, where 
it binds to complex I, uncoupling the oxidation of NADH-linked substrates 
and consequently disrupting the flow of electrons along the electron 
transport chain. In Dauer and Przedborski (2003).  
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than 2 hours (Talpade et al., 2000). Once in the CNS, its brain distribution is 
heterogeneous, paralleling regional differences in oxidative metabolism.  
Rotenone impairs oxidative phosphorylation by inhibiting NADH-ubiquinone 
reductase activity through its binding to the PSST subunit of the 
multipolypeptide enzyme complex I of the electron transport chain (Schuler and 
Casida, 2001). Beside its effects on mitochondrial respiration, rotenone also 
inhibits the formation of tubulin microtubules (Brinkley et al., 1974; Marshall and 
Himes, 1978), an effect relevant to the mechanism of dopaminergic 
neurodegeneration, as excess of tubulin monomers may be toxic to cells 
(Weinstein and Solomon, 1990). Rotenone has been used extensively as a 
prototypic mitochondrial poison in cell cultures, but less frequently in living 
animals. Behaviorally, rotenone-infused rats exhibit reduced mobility, flexed 
posture and in some cases rigidity and even catalepsy (Sherer et al., 2003). 
The potent herbicide N,N’-dimethyl-4-4-4-bypiridinium, commonly known 
as paraquat, is another prototypic toxin known to exert deleterious effects 
through oxidative stress. Paraquat exhibits a striking structural similarity to 
MPP+ and its toxicity is mediated by redox cycling with cellular enzymes that 
present nicotinamide adenine dinucleotide phosphate-diaphorase activity, such 
as neuronal form of nitric oxide synthase, yielding ROS (Przedborski and 
Ischiropoulos, 2005). Although it poorly crosses the BBB spontaneously 
(Shimizu et al., 2001), significant damage to the brain is seen in individuals who 
died from paraquat intoxication and epidemiological studies have suggested an 
increased risk for PD due to paraquat exposure (Liou et al., 1997), but at this 
time, the data and clinical evidence are still inconclusive (Berry et al., 2010). 
Some investigators have reported reduced motor activity and dose-dependent 
loss of striatal dopaminergic nerve fibers and SN neuronal cell bodies in 
paraquat treated mice (Bové et al., 2005). However, this toxin model has shown 
some contradictory results, variable cell death and loss of striatal DA content 
(Miller, 2007) and the effect of this compound in the nigrostriatal dopaminergic 
system are somewhat ambiguous (Freira and Koifman, 2012). 
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1.4.2. Genetic models of PD 
 
With the identification of PD-associated genes and given the fact that the 
chemical-induced animal models do not show all the classical phenotypes of 
PD, animal models based on PD patient gene mutations have been created as 
well. Currently there are many genetic animal models of PD due in different 
model organisms, including mice, Drosophila melanogaster and 
Caernorhabditis elegans. There are also a variety of cell models that have been 
used to glean insight into how mutations in the various PD-related genes lead to 
neuronal dysfunction. These genetic models may better simulate the 
mechanisms underlying the genetic forms of PD, even though their pathological 
and behavioral phenotypes are often quite different from the human condition. A 
number of cellular and molecular dysfunctions have been shown to result from 
these gene defects (Blesa and Przedborksi, 2014) and some studies have 
reported alterations in motor function and behavior in mice models (Hinkle et al., 
2012; Hennis et al., 2013), as well as sensitivities to complex I toxins like MPTP 
that differ from those of wild type mice (Nieto et al., 2012; Dauer et al., 2002). 
However, studies evaluating the integrity of the nigrostriatal dopaminergic 
system in these genetic models failed to find significant loss of dopaminergic 
neurons (Goldberg et al., 2003; Hinkle et al., 2012), suggesting that the 
recapitulation of the genetic alterations in mice is insufficient to reproduce the 
final neuropathological feature of PD. 
Mutations in the SNCA gene are known to cause a rare form of 
autosomal dominant PD, either through isolated point mutation or gene 
multiplication (Lee and Trojanowski, 2006). Numerous α-synuclein transgenic 
mice have been reported using a variety of promoters. It has been shown that 
these mice models may have motor dysfunction and filamentous inclusions that 
initiate neurodegeneration (Giasson et al., 2002), although none of them show 
robust and progressive nigrostriatal degeneration (Ted et al., 2010). The 
phenotypic outcome of the overexpression of α-synuclein in mice depends 
heavily on the promoter used. Of the many vertebrate models, only the mouse  
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prion promoter A53T α-synuclein transgenic mice exhibit the full range of α-
synuclein pathology that is observed in humans, including progressive age-
dependent neurodegeneration (Chesselet et al., 2008). Other transgenic 
models also exhibit gradations of α-synuclein aggregation, but they lack the 
characteristic α-synuclein fibrils that are present in humans with PD and related 
α-synucleinopathies (Chesselet, 2008; Dawson et al, 2010). 
The most frequent genetic cause of autosomal dominant PD is mutations 
in LRKK2 (Zimprich et al., 2004). Several animal and cellular models of LRKK2 
have been reported and they have provided important insight into how 
mutations in this gene may lead to neurodegeneration in PD. Mutations in 
LRKK2 that segregate with PD are concentrated in the GTPase and kinase 
domains but LRKK2 binding partners and regulators of kinase and GTPase 
activity have yet to be confirmed or clarified (Biskup and West, 2009). The 
majority of cases of LRKK2 related PD is characterized pathologically by the 
presence of α-synuclein inclusions, suggesting that these two proteins share 
common pathogenic mechanisms (Ross et al., 2006). In cellular models, 
overexpression of disease causing mutations of LRKK2 are toxic and toxicity is 
kinase and GTP-binding dependent (Smith et al., 2006; West et al., 2007). 
Knockout of LRRK2 in mice suggest that LRRK2 does not play a role in the 
development or maintenance of dopaminergic neurons (Andres-Mateos et al., 
2009) and current transgenic mouse models are not very robust PD models. 
Most of these models have abnormalities in the nigrostriatal system such as 
stimulated DA neurotransmission or behavioral deficits, which are DA 
responsive (Dawson et al., 2010) but it is not yet clear why LRRK2 transgenic 
models do not exhibit more substantial pathology. The utility of the current 
models is likely to be focused on how mutations in LRRK2 lead to early 
dysfunction of the nigrostriatal dopaminergic system. 
Regarding parkin, mutations in this gene are the most common genetic 
cause of early-onset PD (Marder et al., 2010). Knockout of this gene in 
Drosophila leads to mutant flies with reduced lifespan, male sterility and severe 
defects in both flight and climbing abilities, with decreased tyrosine hydroxylase 
levels observed in aged flies and specific degeneration of a subset of  
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dopaminergic neurons (Greene et al., 2003). However, none of the parkin KO 
mice have any substantial dopaminergic or behavioral abnormalities (Goldberg 
et al., 2005) and it has been shown that LB formation and neurodegeneration 
are parkin independent in a mouse model of α-synucleinopathy (von Coelln et 
al., 2006). Some of the parkin knockout mice have subtle abnormalities in the 
dopaminergic nigrostriatal circuit or the locus coeruleus noradrenergic system 
(von Coelln et al., 2004). Interestingly, overexpression of mutant human parkin 
in both Drosophila and mice lead to a progressive degeneration of 
dopaminergic neurons (Lu et al., 2009; Sang et al., 2007). 
 
2. The Endoplasmic Reticulum and Oxidative Stress  
 
 It has been proposed that mitochondrial dysfunction and oxidative 
damage may play a critical role in both aging and neurodegenerative diseases 
(Beal, 2005). Mitochondrial oxidative phosphorylation is the primary source of 
high energy compounds in the cell and the dysfunction of mitochondrial 
metabolism leads to reduced ATP production, impaired calcium buffering and 
generation of ROS (Surmeier et al., 2011). In regards to PD, accumulating 
evidence indicates that oxidative stress contributes to the cascade of events 
leading to the degeneration of dopaminergic neurons in the SN. Postmortem 
brain analyses show increased levels of 4-hydroxyl-2-nonenal, a by-product of 
lipid peroxidation, carbonyl modifications of soluble proteins and DNA and RNA 
oxidation products (Dias et al., 2013). Also, the link between oxidative stress 
and dopaminergic neurons is further supported by modeling the motor aspects 
of PD in animals with toxins that cause oxidative stress such as mitochondrial 
inhibitors like MPTP, rotenone or paraquat. This production of ROS may be the 
trigger for a dysfunction in the protein metabolism in the ER seen in sporadic 
PD. The ER serves many general functions, including protein processing, 
folding and the transport of membrane and secretory proteins, as well as the 
degradation of misfolded protein aggregates, providing and maintaining an 
exclusive oxidized environment of millimolar concentrations of Ca2+ to facilitate 
disulfide bond formation (Calì et al., 2011). This process is believed to  
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contribute to 25% of ROS generated by the cell (Tu and Weissman, 2004). 
Chronic ER stress through endogenous or exogenous insults may further 
increase oxidative stress via protein overload, impaired redox homeostasis, and 
calcium released from the ER, which in turn can augment the production and 
accumulation of mitochondrial ROS, thereby also influencing vital mitochondrial 
functions (Malhotra and Kaufman, 2011). 
 
 2.1 Endoplasmic Reticulum Stress 
 
 The ER is involved in several metabolic processes such as 
gluconeogenesis and lipid synthesis, while also being the major intracellular 
calcium reservoir in the cell (Chaudhari et al., 2014). Newly synthesized 
membrane and secreted proteins enter the ER in an unfolded state, where the 
protein maturation steps required for a proper folding occur. Folding might 
involve post-translational modifications, such as glycosylation or disulfide bond 
formation, assisted by a vast number of chaperones and modifying enzymes 
that also contribute to membrane integration (Braakman and Hebert, 2013). The 
protein-folding machinery in the ER is particularly challenged in specialized 
secretory cells (such as pancreatic β-cells), given the fact that these cells have 
a high demand for protein synthesis, constituting a constant source of stress. 
 Despite all the biological mechanisms dedicated to protein folding, a 
significant portion of newly synthesized polypeptides entering the ER fails to 
acquire a native conformation (Ruggiano et al., 2014). These misfolded 
molecules are retained in the ER and eventually become substrates of the 
ERAD, a set of quality-control mechanisms that clears the ER from harmful 
misfolded proteins (Brodsky, 2012) and plays a key role in ER homeostasis. 
Genetic ablation of several ERAD components leads to embryonic lethality in 
mice (Yagishita et al., 2005; Francisco et al., 2010) and the inactivation of the 
ERAD has tremendous consequences, resulting in the build-up of misfolded 
proteins in the lumen and membrane of the ER, a phenomenon also known as 
ER stress. This occurs when the folding capacity of ER exceeds the capacity of 
ER lumen to facilitate the disposal of misfolded proteins. Consequently, the ER  
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elicits a protective or adaptive response which involves an intricate set of 
signaling pathways that will be activated to compensate damage and to restore 
the cell back to its normal state of homeostasis (Walter and Ron, 2011). These 
biological processes are collectively called the UPR. 
 
2.2 The UPR 
 
The UPR is a global stress network that integrates information about the 
protein-folding status in the ER lumen to the nucleus and cytosol to decrease 
the unfolded protein load, controlling decisions on cell fate through a variety of 
complementary mechanisms (Schroder and Kaufman, 2005) (Fig. 2). The 
primary function of the UPR signaling is promoting the cell survival under hostile 
conditions. When cells undergo irreversible ER stress, UPR is responsible for 
the elimination of damaged cells through apoptotic mechanisms, some of which 
appear to be specific to ER stress and others that are included in general 
apoptotic pathways (Xu et al., 2005). Even though the UPR is linked to protein-
folding stress under normal and pathological conditions, recently it has been 
shown that some of its components can regulate various processes, from lipid 
and cholesterol metabolism, to inflammation and cell differentiation (Rutkowski 
and Hedge, 2010). These alternative UPR outputs are thought to derive from 
the complex crosstalk between different stress and metabolic pathways, 
showing that UPR components are part of distinct regulatory modules that 
orchestrate the fine-tuning of essential homeostatic processes (Hetz, 2012). 
Two distinct phases of cellular responses are observed in vertebrate cells 
undergoing ER stress. First, an inhibition of general protein translation occurs 
coupled with a selective degradation of mRNA encoding for certain proteins 
located in the ER and a bulk degradation pathway termed ER-phagy, a process 
that eliminates damaged ER and abnormal protein aggregates through the 
lysosomal pathway (Hetz, 2012). This first wave of cellular responses reduces 
the protein influx into the ER to allow adaptive and repair mechanisms that 
reestablish homeostasis. A second wave of events triggers a massive gene-
expression response through the regulation of three distinct ER proximal UPR  
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transmembrane proteins: IRE1α, ATF6α and PERK. Under normal physiological 
conditions, all three effectors are negatively regulated by the ER chaperone 
GRP78/BIP, which suppresses their activity by binding to their luminal ends 
(Bertolotti et al., 2000). Under conditions of ER stress and increase in unfolded 
proteins, GRP78 dissociates from the transmembrane proteins, releasing the 
inhibition and eliciting the response. Activation of the ER pathways helps to fight 
the cellular stress through the combined actions of suppressing the translation 
of new proteins, inducing ER chaperones that promote protein refolding and 
activating the proteasome to degrade misfolded/unfolded proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Schematic representation of the UPR. The UPR stress sensors IRE1α, PERK and 
ATF6α transduce information about the folding status of the ER to the cytosol and nucleus to 
restore protein-folding capacity. Through its actions, the stress sensors mediate the attenuation 
of protein translation, the expression of protein-folding chaperones and many other genes 
involved in the UPR. In Hetz (2012). 
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2.2.1 PERK signaling 
 
PERK is a type I ER transmembrane protein kinase with a luminal 
domain and a cytoplasmic domain that has kinase activity. Upon ER stress, BIP 
releases the luminal domain of PERK, which then dimerizes and 
autophosphorylates to become active. Following trans-autophosphorylation, this 
kinase phosphorylates the alpha subunit of eIF2, inactivating it by Ser-51 
phosphorylation and attenuating protein translation. This inhibitory effect of 
translation helps to alleviate ER stress by decreasing the overload of misfolded 
proteins and thereby protecting the cells under conditions where proteins 
cannot achieve proper folding (Fels and Koumenis, 2006). Translation 
attenuation is followed by increased clearance of the accumulated proteins from 
the ER by ERAD and expression of pro-survival genes (Chakrabarti et al., 
2012). Interestingly, eIF2α phosphorylation increases the translation of selective 
mRNAs that contain inhibitory upstream open reading frames within their 5’UTR 
that prevent translation in unstressed cells, such as the mRNA of ATF4 (Vattem 
and Wek, 2004). ATF4 is a member of the cAMP response-element-binding 
family of transcription factors and up-regulates a subset of UPR genes that 
function in resistance and control of oxidative stress, metabolism, protein folding 
and glutathione biosynthesis (Harding et al., 2000). Under severe ER stress 
conditions, ATF4 contributes to the induction of cell death through the control of 
the transcription of pro-apoptotic BCL-2 family members including p53 
upregulated modulator of apoptosis and BIM, in addition to GADD34 and 
CHOP, a protein composed of an N-terminal transcriptional activation domain 
and a C-terminal bZIP that promotes apoptosis by the repression of Bcl2 
expression and sensitization of cells to ER-stress inducing agents (Galehdar et 
al., 2010). 
Furthermore, PERK can also phosphorylate Nrf2 (Cullinan et al., 2003), a 
member of a subfamily of bZIP transcription factors (Moi et al., 1994) that binds 
to a sequence known as the ARE, a response element found in many 
cytoprotective genes (Gao et al., 2014). In a stress-free cellular environment, 
Nrf2 is rapidly degraded by the proteasome. Degradation of Nrf2 is triggered by 
polyubiquitination through the cytoskeletal anchor Keap1/Cul3 ubiquitin ligase 
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that acts as a substrate adaptor to bring Nrf2 into the E3 complex (Kobayashi et 
al., 2004). In the presence of cellular stress, Nrf2 dissociates from Keap1 
through the modification of reactive cysteine residues of Keap1 (Kobayashi et 
al., 2006) and is translocated to the nucleus, where it induces the expression of 
a wide variety of downstream target genes, that include several cytoprotective 
phase II detoxification and antioxidant enzymes and signaling proteins to 
regulate drug metabolism, antioxidant defense and oxidant signaling (Cullinan 
and Diehl, 2004). Through its regulation of oxidant levels and oxidant signaling, 
Nrf2 participates in the control of several functions such as autophagy, 
inflammasome signaling, apoptosis and UPR, exhibiting multiple protective 
effects against toxicity (Ma, 2013). 
 
 
2.2.2. IRE1α signaling  
 
IRE1α is a type I transmembrane protein ubiquitously expressed 
(Tirasophon et al., 1998) with dual enzymatic activities, consisting of an N-
terminal ER luminal domain and a serine/threonine kinase domain plus a C-
terminal RNase domain located in the cytosol (Lee et al., 2008). Upon 
accumulation of unfolded/misfolded proteins in the ER and under conditions 
identical to those that activate PERK (Hetz et al., 2011), IRE1α dimerizes and 
oligomerizes while stimulating trans-autophosphorylation which leads to the 
activation of the RNase domain (Korennykh et al., 2009). Afterwards, activated 
IRE1α excises a 26-nucleotide intron from the XBP1 mRNA through its RNase 
domain, causing a translational shift in the codon reading frame that generates 
a new COOH terminal end and leads to the expression of a more stable and 
active transcription factor, XBP1s, that will translocate to the nucleus and 
regulate a subset of UPR target genes related to folding, ER/Golgi biogenesis 
and ERAD (Jiang et al., 2015), which differ in different tissues or under different 
conditions of ER stress (Acosta-Alvear et al., 2007). Furthermore, IRE1α can 
also degrade ER-bound mRNAs through cleavage at stem-loop and non-stem-
loop sites, a process known as RIDD. RIDD helps to reduce the number of  
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proteins that enter the ER, further alleviating ER stress (Hollien et al., 2009). In 
the event of persistent ER stress, activated IRE1α can also promote apoptotic 
pathways by activating ASK1 and JNK, through interaction with TRAF2 (Urano 
et al., 2000; Nishitoh et al., 2002). 
 
2.2.3. ATF6α signaling 
 
Another UPR pathway is mediated by ATF6α, a type II ER 
transmembrane protein that contains bZIP domains in its cytosolic region (Haze 
et al., 1999). ATF6α is synthesized as an inactive precursor, bound to the ER by 
a transmembrane segment. Under ER stress conditions, ATF6α precursor 
translocates to the Golgi where it is cleaved in a process termed regulated 
intramembrane proteolysis. Firstly, ATF6α is cleaved by a site 1 protease which 
removes most of its luminal domain, followed by the removal of an 
intramembrane region by a site 2 protease, releasing an active N-terminal 50 
kDa cytosolic fragment (ATF6f) (Nakka et al., 2014). This fragment operates as 
a transcriptional factor by binding to the ER stress response element within the 
promoter region of target genes, which will then up-regulate the expression of 
many UPR genes related to ERAD (Shen and Prywes, 2005). 
Both processing of ATF6 and IRE1α-mediated splicing of XBP1 mRNA 
are required for full activation of the UPR. Furthermore, it is thought that the 
ATF6 and IRE1α pathway merge through the regulation of XBP1 activity: ATF6 
increases the amount of XBP1 mRNA whereas IRE1α removes the 26-
nucleotide intron, increasing XBP1 transactivation potential. Together with 
XBP1s, ATF6f will increase the transcription of target genes that expand ER 
size and increase its protein folding capacity to promote cell survival (Lee et al., 
2002).  
 
2.3 ER Stress in PD 
 
Some reports have revealed that the UPR is an early event in PD and the 
presence of ER stress in human tissue derived from PD patients has been 
reported (Hoozemans et al., 2012). Immunoreactivity for phosphorylated PERK 
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and eIF2α in dopaminergic neurons of the SN has been described in PD post-
mortem tissue, and the neurons presenting activated PERK were also positive 
for α-synuclein inclusions (Hoozemans et al., 2007). Furthermore, it has been 
demonstrated that ER stress-responsive proteins such as homocysteine-
induced endoplasmic reticulum protein are upregulated in the SN of PD patients 
and co-localize with LBs (Conn et al., 2004; Slodzinski et al., 2009). Cellular 
studies in yeast have shown that overexpression of wild type and mutant α-
synuclein triggers chronic ER stress inducing cell death (Cooper et al., 2006) 
and reports in complementary model organisms demonstrated that the earliest 
defect following α-synuclein expression is a block in ER to Golgi vesicular 
trafficking (Smith et al., 2005; Gitler et al., 2008). The involvement of the UPR in 
PD has also been shown in cellular and in vivo models using 6-OHDA, MPTP 
and rotenone (Blesa and Przedbroski, 2014). Generation of ROS by these 
neurotoxins leads to a rapid accumulation of oxidized proteins that can activate 
the UPR. Moreover, neuronal cells treated with PD-triggering toxins present 
phosphorylation of IRE1α and PERK as well as induction of their downstream 
targets (Ryu et al., 2002). Experiments carried out using neuronal cultures from 
PERK KO mice revealed an increased sensitivity of these cells against 
treatment with 6-OHDA, suggesting that neurons lacking this protein were 
unable to properly activate the UPR and that an early UPR response may be 
neuroprotective for the dopaminergic neurons (Lindholm et al., 2006).  Similarly, 
ATF6α deficient mice are more susceptible to neurotoxin-induced 
neurodegeneration at the SN (Egawa et al., 2010) 
Further evidence for a role of the UPR in PD pathogenesis comes from a 
juvenile onset autosomal recessive form of PD that is caused by mutation of the 
parkin gene, which compromises the ubiquitin ligase function of the protein. 
This leads to the accumulation of cytotoxic fibrils and protein aggregates in the 
ER of SN neurons (Imai et al., 2001), that result in ER stress and consequently 
cell death. Expression of wt parkin, on the other hand, can restore proteasome 
function, which was shown to be impaired in SN neurons in PD (McNaught and 
Jenner, 2001), and it has a pro-survival activity against ER stress due to 
modulation of ERAD/proteasome pathway (Imai and Takashi 2004).  
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 Although these reports suggest that ER stress occurs in affected SN 
neurons in PD brain and that it may trigger ROS production and redox deviation 
in the ER, general characterization of ER stress markers is still very poor and 
proximal signaling components (ATF6α, XBP1s, etc.) remain to be properly 
measured. The precise mechanisms of interplay between oxidative stress and 
ER stress in dopaminergic neurons have been sparsely described and whether 
ER stress plays a role in oxidative stress and anti-oxidant elicited neuronal 
response is currently unknown, as the mechanisms leading to ER stress in PD 
and the actual impact of the UPR on the degeneration cascade in the disease 
are just starting to be uncovered (Mercado et al. 2013). 
 
3. Glutathione S-transferases 
 
 GSTs are a class of abundant proteins found in most tissues that function 
as xenobiotic metabolizing enzymes in eukaryotes. This supergene family of 
enzymes catalyses the conjugation of nucleophilic thiol-reduced GSH to a 
variety of electrophiles, forming water-soluble GSH conjugates that are readily 
transported out of the cell via membrane-bound efflux pumps (Board and 
Menon, 2013). They are an important cellular defense against numerous 
artificial and naturally occurring environmental agents (Strange et al., 2000) and 
GSTs’  substrates include polycyclic aromatic hydrocarbon epoxides derived 
from the catalytic actions of phase 1 cytochrome P450s as well as numerous 
by-products of oxidative stress (Strange et al., 2000). In addition to their role in 
detoxification, GST isozymes have other characteristics and functions such as 
the regulation of MAPKs and participation in steroid synthesis, tyrosine 
degradation and dehydroascorbate reduction (Tew and Townsend, 2012; Wu 
and Dong, 2012). Furthermore, the deletion of certain genes that encode for 
GST isoforms has been linked to an increased susceptibility to bladder, colon, 
skin and possibly lung cancer (Hayes and Pulford, 1995) and linked to a change 
in drug response (Layton et al., 1999; Roy et al., 2001). 
 GSTs are divided into two main families: cytosolic or soluble GSTs, and 
microsomal. Microsomal GSTs have been described as membrane-associated 
proteins and are structurally distinct from cytosolic GSTs, though they still 
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maintain an ability to catalyze the conjugation of GSH to electrophiles (Hayes et 
al., 2005). Cytosolic GSTs are expressed in all aerobic organisms (Ketterer, 
2001) and a single GST unit consists of an N-terminal α/β-domain that operates 
as a GSH binding site and an all-α.helical domain for substrate binding that 
facilitates catalysis through proton abstraction from GSH in proximity to the 
GSH binding site (Dirr et al., 1994). Structural studies have shown that GSTs 
are typically monomeric but catalytically active as homo- or heterodimers 
composed of 25-30 kDa subunits (Hayes et al., 2005) and are divided into eight 
classes: alpha, kappa, mu, pi, sigma, theta, zeta and omega (Mannervik et al., 
2005).  
In the human brain, the active GSTs are composed of dimers containing 
alpha, mu or pi class GST monomers. GST mu is the most highly expressed 
isoform in the brain followed by GSTP and then GST alpha (Smeyne et al., 
2013). Cellular localization studies have shown that GSTP and GST mu are 
expressed in neurons, astrocytes and oligodendrocytes, but it has been found 
that only GST pi is found in the dopaminergic neurons of the SN (Smeyne et al., 
2007), a region that is particularly sensitive to oxidative stress due to the 
presence of endogenous dopamine, iron and neuromelanine. The distribution of 
GSTs in the brain appears to also be age dependent (Carder et al., 1990).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Detoxification scheme for glutathione 
conjugation. Scheme of detoxification of 1-chloro-2, 4-
dinitrobenze through catalytic thioether formation. GST – 
Glutathione S-Transferase; GSH – Glutathione. Tew and 
Townsend, 2012 (adapted). 
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3.1. Glutathione S-transferase Pi 
 
 GSTP is one of the most extensively studied GSTs and has been 
implicated in the protection of cells from ROS-inducing agents due to its ability 
to alter levels of cellular glutathione in response to production of ROS, 
ameliorating the oxidative milieu (Tew and Ronai, 1999). Mainly found in the 
cytoplasm and widely distributed in a range of tissues (Suzuki et al., 1987), 
GSTP is induced by exposure to electrophiles. At the transcriptional level GSTP 
is regulated mainly by the GSTP enhancer 1 element which is recognized by 
Nrf2 (Suzuki et al., 2005). In contrast to the mouse that has two pi class GST 
genes (Bammler et al., 1994), humans have a single functional GSTP gene 
termed GSTP1 located in chromosome 11q13 (Board et al., 1989). Single 
nucleotide polymorphisms (SNPs) in the GSTP1 gene have been found and 
correlated with several malignancies such, as the development and progression 
of Hodgkin’s and non-Hodgkin’s lymphoma, and cancer drug response 
(Lourenço et al., 2009). These polymorphisms cause a steric change at the 
substrate binding site of the enzyme without affecting the GSH binding affinity 
(Ali-Osman et al., 1997). 
GSTP has also been shown to protect cells from ROS by modulating S-
glutathionylation of proteins following oxidative and nitrosative stress, a post-
translational modification that consists of the addition of GSH to low pKa 
cysteine residues of target proteins (Tew 2007). Protein cysteines are 
evolutionarily highly conserved and sparingly used throughout the proteome, 
suggesting a tight control of cysteine-dependent biological functions. They have 
a wide-ranging reactivity towards oxidants, which depends on their pKa (Dalle-
Donne et al., 2007; Rutkevich and Williams, 2012). It is currently believed that 
the type of cysteine oxidation controls the biological response as well as the 
fate of the oxidized protein (Finkel, 2011). Certain types of cysteine oxidation 
may occur preferentially in subcellular compartments where the redox 
environment may be facilitating these oxidations, such as the ER (Chakravarthi 
et al., 2006). S-glutathionylation generally occurs when a cysteine within the 
protein forms a disulfide bond with GS-, which can occur either in response to 
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endogenous oxidative or nitrosative stress mediated signaling events or from 
exposure to external environment drug treatments (Townsend, 2007). A wide 
range of chemicals can induce S-glutathionylation such as hydrogen peroxide, 
glutathione disulfide, diamide and various nitric oxid donors (Townsend, 2007; 
Townsend et al., 2008). S-glutathionylation has been associated with the 
stabilization and protection of proteins against irreversible oxidation of critical 
cysteine residues, and with the regulation of protein functions and transcription. 
These proteins include enzymes with catalytically important cysteines, 
particularly those involved in protein folding and stability, nitric oxide regulation 
and redox homeostasis, such as kinases, phosphatases, heat shock proteins, 
proteins involved in energy metabolism and transcription factors (Tew et al., 
2012).  
It has been shown that Keap1 is modified by S-glutathionylation (Zhang 
et al 2010). This protein has high cysteine content, making it an excellent 
candidate for this post-translational modification. Interestingly, GSTP itself is 
subject to S-glutathionylation, which reduces its enzymatic activity against 
chemical substrates and promotes its multimerization (Dalle-Donne et al 2007). 
Altered levels of S-glutathionylation in some proteins have been associated with 
numerous pathologies, many of which linked to stress within the ER (Janssen-
Heininger et al 2013).  
Besides being involved in cell redox homeostasis, GSTP also has a 
number of other functions such as catalyzing degradation of nitro-compounds 
(Lo Bello et al., 2001), and participating in reactions involving stress kinases 
(Adler et al., 1999). In regards to the latter, it has been shown that GSTP1 
monomer can act as a ligand-binding protein controlling the catalytic activity of 
JNK (Adler et al., 1999; Castro-Caldas et al., 2012), an interaction that involves 
the C-terminal region of GSTP and of JNK (Monaco et al., 1999), preventing c-
Jun phosphorylation and inhibiting the subsequent trigger of the cell death 
cascade. Under conditions of oxidative stress,  
GSTP dissociates from JNK, which may then be phosphorylated and 
consequently phosphorylate its downstream substrates (Yin et al., 2000). It has 
also been shown that after systemic administration of MPTP, GSTP expression 
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is significantly increased in glial cells in the vicinity of dopaminergic neurons cell 
bodies and fibers (Castro-Caldas et al., 2009). 
The creation of two GSTP KO strains has been reported, one involving 
mouse GSTP1 (GSTP1-1) and the second inactivating both genes (Henderson 
et al., 1998), and all studies reported so far involved the double KO mouse 
strain (GSTP1/2 null mice). These mice do not present striking or lethal 
phenotypes and have been mainly used to explore the role of GSTP in 
tumourigenesis (Board, 2007). The results suggest that the contribution of 
GSTP to tumourigenesis is multifaceted; GSTP1/2 null mice are more sensitive 
to a two-stage skin tumourigenesis model (Henderson et al., 1998) showing a 
detoxification role for GSTP.  
Furthermore, it has been shown that GSTP KO mice are more susceptible to 
the neurotoxic effects of MPTP than their wild type counterparts. Administration 
of MPTP induced a demise of nigral dopaminergic neurons together with the 
degeneration of striatal fibers at an earlier timepoint in the GSTP KO mice when 
compared to the wild type counterparts. It has also been shown that in vivo 
GSTP can act as an endogenous regulator of the MPTP-induced cellular stress 
by controlling JNK activity through protein-protein interactions (Castro-Caldas et 
al., 2012). The various contributions of GSTP to carcinogenesis and other 
biological processes reflect the mounting evidence that some GSTs participate 
in cell signaling pathways that are independent of their drug and xenobiotic 
detoxification roles. 
 
3.1.1. GSTP in PD 
 
There have been multiple reports concerning a role for GSTP in PD, both in 
cellular and animal models. It was demonstrated that over-expression of wild-
type GSTP1 before treatment with rotenone effectively protected Neuro2A cells 
by reducing oxidative stress, cell death, neurite loss and attenuating PERK 
activation and CHOP induction, all of which are important components of 
neurodegeneration in PD progression (Oakes and Papa, 2015; Shi et al., 2009), 
and GSTP1 mutants with low catalytic activity had a diminished effect, providing 
compelling evidence that GSTP’s biological functions effectively reduced 
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oxidative stress and the associated ER stress (Shi et al., 2009). Also, using 
primary cultured dopaminergic cells harvested from the SN of MPTP resistant 
mice (Hamre et al., 1999), Smeyne and collaborators have shown that by 
inhibiting GSTP there was an increase in the amount of MPP+-induced neuronal 
death (Smeyne et al., 2007). Administration of MPTP to mice lacking GSTP also 
showed altered protein ubiquitination and increased susceptibility to UPS 
damage and inactivation (Carvalho et al., 2012). Furthermore, reports have 
shown that by mutating the parkin gene in Drosophila and deleting the GSTS1 
gene, the loss of dopaminergic neurons is enhanced and overexpression of 
GSTS1 ameliorates this neurodegeneration (Whitworth et al., 2005).  
The analysis of the SN in the post-mortem brain of PD patients has 
revealed a substantial reduction of GSH levels and low activity of enzymes 
related to the de novo synthesis of GSH that seems to be specific to this 
pathology since changes in GSH were not detected in other neurodegenerative 
diseases (Di Monte et al., 1992; Sian et al., 1994; Pearce et al., 1997). Another 
study that compared ventricular cerebrospinal fluid from PD and normal control 
subjects, has shown differences in proteins expression in PD individuals, 
namely in GSTP1-1 (Maarouf et al., 2012). Epidemiological studies have shown 
that decreased GSTP expression is a significant risk factor in PD and that 
GSTP wild type allele is an individual protective genetic trait in idiopathic PD 
(Golbe et al., 2007). Furthermore, it has been found an association between the 
A313G polymorphism in GSTP1 and sporadic PD (Kelada et al., 2003; Vilar et 
al., 2007), suggesting that the decreased conjugation of some GSTP substrates 
may be relevant to the etiology of PD. 
 
4. TUDCA as a therapeutic approach 
 
 4.1 UDCA and TUDCA: endogenous functions and therapeutic 
properties 
 
 Bile acids are detergent molecules synthesized in the liver from neutral 
sterols (Russell and Setchell, 1992). In most animals (including humans) bile 
acids are produced mainly from the cholesterol metabolic pathway, and 
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complete synthesis requires several enzymes in processes tightly regulated by 
nuclear hormone receptors and other transcription factors (Chiang, 2004). Bile 
acids are the major constituents of the bile and play crucial biological functions 
such as the solubilization of dietary fats and fat-soluble vitamins to improve 
absorption in the intestinal lumen. There has been a growing interest in the last 
decades in these acidic steroids since the discovery of their role in important 
physiological phenomena, including liver and intestinal pathology and 
pharmacology (Paumgartner and Beuer, 2004). In fact, some bile acids are 
cytotoxic molecules involved in increased cell proliferation and cancer 
development in the intestinal tract (Bayerdorffer et al., 1993), and cell death by 
necrosis and apoptosis, a key event during hepatobiliary diseases (Patel and 
Gores, 1995). However, not all bile acids are toxic and it has been suggested 
that this is due to subtle changes in their chemical structure (Hofmann and 
Roda, 1984): hydrophobic bile acids can induce cell death in liver cells during 
cholestasis, by activating both ligand-dependent and –independent death 
receptor oligomerization and signaling the mitochondrial pathway of apoptosis 
(Faubion et al., 1999; Yerulshami et al., 2001), while hydrophilic bile acids can 
be cytoprotective through the activation of cell survival pathways such as MAPK 
and phosphoinositide 3-kinase, preventing mitochondrial dysfunction and 
consequently apoptosis (Schoemaker et al., 2004). 
 UDCA is an endogenous hydrophilic bile acid currently approved for the 
treatment of certain liver diseases such as primary biliary cirrhosis, due to its 
choleretic effects and ability to protect hepatocytes from hydrophobic bile acids 
(Lazaridis et al., 2001). UDCA accounts for 4% of the bile acid pool in the 
human body (Bachrach and Hofmann, 1982) and there is strong evidence that 
its cytoprotective effects result from the ability to reduce the apoptotic threshold 
in several cell types by modulating classical mitochondrial pathways (Rodrigues 
et al., 1998). This steroid can also activate specific nuclear receptors and G 
protein-coupled receptors influencing the expression of genes that encode 
proteins involved in the regulation of glucose, fatty acid, lipoprotein synthesis, 
energy metabolism and the regulation of their own synthesis (Hylemon et al., 
2009). Further studies have shown that UDCA as well as its taurine conjugate 
TUDCA also inhibit oxygen-radical production and reduce caspase activation 
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(Amaral et al., 2009). Moreover, it has also been shown that UDCA and TUDCA 
can prevent UPR dysfunction and ameliorate ER stress. It does so by improving 
the protein folding and assisting in the transfer of mutant proteins and also 
through the inhibition of eIF2α (Omura et al., 2013). Other articles have shown 
that TUDCA can activate PERK (Gani et al., 2015; Liu et al., 2015). UDCA and 
TUDCA have also been shown to have ameliorating effects in inflammatory 
metabolic diseases including atherosclerosis, diabetes, renal disease and 
stroke (Vang et al., 2014). 
 
 
 4.2 TUDCA in neurodegenerative diseases 
In recent years, neuroprotective functions have been attributed to 
TUDCA (Rodrigues and Steer, 2000). Studies in vitro using millimolar 
concentrations of TUDCA have demonstrated its inhibitory effects on the 
thermal aggregation of different proteins (Song et al., 2011; Berger and Haller, 
2011). It has been thoroughly demonstrated that TUDCA can cross the BBB in 
humans (Parry et al., 2010), reducing the accumulation of toxic aggregates in 
different experimental models of neurodegenerative diseases, acting as a 
mitochondrial stabilizer and anti-apoptotic agent with cytoprotective properties 
(Keene et al., 2002; Elia et al., 2015). Furthermore, TUDCA is bioavailable and 
presents a low toxicity profile, which represents a therapeutic advantage and 
has led to an increasing attention as potential treatment for neurodegenerative 
conditions. 
The protective role of TUDCA has been extended to numerous mouse 
models of neurological disorders. Several reports have shed light on the 
neuroprotective effects of TUDCA in Alzheimer’s disease (Ramalho et al., 
2008). In vitro studies have shown that TUDCA inhibits Aβ-induced apoptosis 
(Solá et al., 2006; Viana et al., 2010). Using primary rat cortical neurons, it was 
shown that TUDCA activates pro-survival signaling cascades decreasing Aβ 
mediated apoptosis (Solá et al., 2003). In regards to animal models, TUDCA 
treatment significantly attenuated Aβ deposition in the brain of APP/PS1 mice 
after disease onset while also reducing the amyloidogenic processing of  
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amyloid precursor protein, ameliorating memory deficits (Nunes et al., 2012; Lo 
et al., 2013). This is accompanied by a decrease in the glial activation and 
reduced pro-inflammatory cytokine expression, partially rescuing synaptic loss 
(Dionísio et al., 2015). Furthermore, it was shown that TUDCA modulates 
synaptic deficits induced by Aβ, preventing the reduction in dendritic spine 
number and decreasing spontaneous miniature excitatory synaptic activity 
(Ramalho et al., 2013). 
Concerning HD, cell cultures treated with TUDCA significantly increased 
neuronal survival by inhibiting the release of cytochrome c in isolated 
mitochondria, DNA fragmentation and caspase activation, consequently 
inhibiting apoptosis (Keene et al., 2001; Rodrigues et al., 2000). The protective 
effect of TUDCA is also seen in toxin models of HD, with TUDCA preventing 
striatal degeneration and ameliorating locomotor and cognitive deficits in vivo 
(Keene et al., 2001) and genetic models of HD, in which systemic administration 
of TUDCA led to a significant reduction in striatal neuropathology (Keene et al., 
2002). In fact, clinical trials are currently underway to study the tolerability and 
efficacy of TUDCA in patients with HD and amyotrophic lateral sclerosis (Cortez 
and Sim, 2014). 
In the context of PD, a recent study that screened more than 2000 
compounds identified UDCA as a highly promising drug therapy for future 
neuroprotective trials in PD (Mortiboys et al., 2013). TUDCA has also been 
found to play a role as a neuroprotective molecule in PD by protecting against 
apoptosis and regulating JNK activity and cellular redox thresholds. TUDCA 
treatment conferred protection against rotenone-induced toxicity and non-
transgenic lines were fully protected by this bile acid, with some transgenic 
strains showing increased survival with TUDCA treatment (Ved et al., 2005). In 
mice models, the neuroprotective role of TUDCA has also been validated 
against MPTP toxicity. In a study with mice lacking GSTP, pre-treatment with 
TUDCA significantly reduced the depletion of dopaminergic neurons and 
dopaminergic fiber loss caused by MPTP. TUDCA also modified the cellular 
environment and attenuated the deleterious events of MPTP by blocking ROS 
production and JNK activation in GSTP null mice (Castro-Caldas et al., 2012).  
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Further support for the protective role of TUDCA in PD comes from reports of 
the transplantation of nigral dopamine neurons into rodent models: parkinsonian 
rats were transplanted with nigral dopamine neurons from fetal rats incubated 
with 50 μM TUDCA or saline. Rats treated with dopamine neurons incubated in 
TUDCA exhibited a significant reduction in cell death rates, as histological 
analysis of the transplanted cells revealed a significantly greater number of 
tyrosine-positive cells in the TUDCA-treated cells versus the saline-treated cells 
(Duan et al., 2002). These results suggest that TUDCA can enhance survival of 
transplanted dopamine neurons via reduction of apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
5. Objectives 
 
 Previous studies in our laboratory have shown that there may be a role 
for GSTP in PD. We hypothesized a potential neuroprotective role of this GST 
isoform, and intend to clarify its role by studying the Nrf2-mediated regulation 
and ER stress response in the context of MPTP-induced brain lesions. The 
work relied on the use of a GSTP KO mouse model and aimed to contribute to a 
better understanding of the molecular mechanisms underpinning loss of 
dopaminergic neurons in PD, which may lead to the development of novel 
therapeutic strategies. 
 The main objectives of this study were: 
 
(a) Characterize the effects of the MPTP insult on the ER stress 
response in C57BL/6 wt and GSTP null mice brain; 
 
(b) Determine the effect of GSTP deletion in the context of MPTP-
induced ER stress; 
 
(c) Evaluate the potential neuroprotective effect of TUDCA on 
MPTP oxidative driven ER stress. 
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II. MATERIALS and METHODS 
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1. Animals and Treatment  
 
All animal experiments were carried out in accordance with the 
institutional procedures and Portuguese and European guidelines for the care 
and use of animals (Diário da República, 2.ª série N.º 121 of 27 June 2011; and 
2010/63/EU European Council Directive), and methods were approved by  the 
Direcção Geral de Alimentação e Veterinária (DGAV, reference 021944 and the 
Ethical Committee for Animal Experimentation of the Faculty of Pharmacy, 
University of Lisbon.   
C57BL/6 Gstp1/p2 null mice (Cancer Research UK) were re-derived and 
maintained at the Gulbenkian Institute of Science Animal House (Oeiras, 
Portugal). This line has a double-knockout of both Gstp genes (Gstp1 and 
Gstp2), deleted by homologous recombination (Henderson et al., 1998). The 
animals were housed under standardized conditions on a 12-h light–dark cycle 
with free access to a standard diet and water ad libitum.  
Animals were treated only with TUDCA or MPTP, or treated with TUDCA 
prior to MPTP administration. TUDCA was dissolved in phosphate-buffered 
saline (PBS), pH 7.4, and was injected intra-peritoneally (i.p.) for three 
consecutive days (50 mg/kg body weight). MPTP was administered i.p. at a 
single dose of 40 mg/kg (Saporito et al. 2000). In TUDCA and MPTP co-
treatments, TUDCA daily administration (50 mg/kg body weight) began on day 
0, followed by i.p. administration of MPTP at a single dose (40 mg/kg body 
weight) on day 3, 6 h after the last TUDCA injection (Keene et al., 2001; Castro-
Caldas et al., 2009). Control mice received saline alone. Mice were sacrificed 3 
or 6 h after neurotoxin or vehicle administration. Samples from saline-treated 
and TUDCA-treated mice were collected prior to MPTP injection.  
The time course studies were carried out in three independent 
experiments (n=3) with groups of three to six mice.  The schematic chronogram 
of TUDCA and MPTP administration is shown in Figure 4.  
After being anesthetized with sodium pentobarbital (50 mg/kg, i.p.), mice 
were decapitated and brains were quickly removed and placed in fresh PBS. 
Brains were then placed on their ventral surface onto a mouse brain matrix 
(Agar Scientific), and a slice between Bregma −2.5 and Bregma −3.8 was 
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isolated. This removed brain slab was placed flat and the entire cortex region 
was dissected. The specific pieces of interest were flash frozen under liquid 
nitrogen until further use. Preliminary studies have shown that in the saline 
control samples the evaluated parameters did not change through the time 
course; therefore, collection of control tissues was carried out at injection day 1, 
reducing the number of animals needed in these studies. The time course study 
was carried out in three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - Schematic representation of C57BL/6 wild type and GSTP null mice 
treatment course. Mice were i.p. injected with TUDCA (50 mg/kg body weight) for 
three consecutive days. MPTP was administered i.p. at a single dose of 40 mg/kg 
body weight.  
Mice were divided into 4 main groups: i) control mice that received saline (group 1); 
ii) mice that received only TUDCA injections for 3 consecutive days, and were 
sacrificed 6 h after the last TUDCA administration (group 2); iii) mice treated with 
MPTP, that were sacrificed 3 h (MPTP, 3h) or 6 h (MPTP, 6h) after MPTP injection 
(group 3 and 4); iv) mice that received daily injection of TUDCA beginning on day 
1, followed by i.p administration of MPTP on day 3, and were sacrificed 3 h (T+M, 
3h) or 6 h (T+M, 6h) after MPTP injection (group 5 and 6). Samples for Western 
blotting were taken 6 h after the last TUDCA injection, or 3 and 6 h after MPTP 
administration. 
(M – MPTP administration; T – TUDCA administration; X – Animal Sacrifice) 
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2. Western Blot Analysis 
 
Tissue samples were homogenized in ice cold PBS using a Potter-
Elvehjem homogenizer, followed by a 10 min centrifugation at 4ºC, after which 
the pellet was collected. For total protein extracts, lysis buffer (NaVO3 200 mM, 
NaF 1 mM, DTT 1 mM) plus Complete Mini protease inhibitors cocktail was 
added to the pellet. Lysates were sonicated on ice, five times for 5 s each, 
centrifuged at 13,000×g for 15 min at 4ºC, and the supernatant was recovered. 
Total Protein concentration was determined by the Bradford method (Bradford, 
1976) using Bio-Rad’s Protein Assay Reagent.   
Tissue extracts with 100 μg of total protein were added (1:5) to 
denaturing buffer (0.25 mM Tris–HCl, pH 6.8, 4% sodium dodecyl sulfate 
(SDS), 40% glycerol, 0.2% bromophenol blue, 1% β-mercaptoethanol), boiled 
for 5 min, resolved on 12,5% SDS-polyacrylamide gel electrophoresis, and 
electrotransfered to PVDF membrane. The membrane was blocked with 5% 
non fat dry milk in Tris-buffered saline with 0.1%Tween-20, for 1 h at room 
temperature and incubated overnight at 4°C with the primary antibodies (Table 
2). After the membranes were washed for three times with Tris-buffered saline 
with 0.1% Tween-20 for 15 minutes each and incubated with horseradish-
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies for 1 h at 
room temperature. Afterwards, the membranes were rinsed in Tris-buffered 
saline with 0.1% Tween-20 three times for 15 minutes each, and the 
immunocomplexes were detected with Pierce™ ECL Western Blotting 
Substrate (32106; ThermoScientific) or SuperSignal West Femto Maximum 
Sensitivity Substrate (34096; ThermoScientific). Densitometric analyses were 
performed using the Image Lab software Version 5.1 Beta after scanning with 
ChemiDoc™, both from Bio-Rad Laboratories (Hercules, CA, USA).  
Membranes were then stripped, with stripping solution (1.5% glycine, 40% 
glacial acetic acid, 1% SDS, 10% Tween 20) for 10 min, and rinsed several 
times in TBS-T. Stripped membranes were then blocked as previously 
described and incubated with mouse anti-β-actin primary antibody, followed by 
incubation with horseradish peroxidase-conjugated anti-mouse secondary 
antibody. β-actin expression was used as a loading control.  
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3. Immunohistochemistry 
 
Mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and 
transcardially perfused with ice-cold PBS, followed by 4% paraformaldehyde–
PBS, pH 7.4. After perfusion, brains were quickly removed and fixed by 
immersion, at 4°C for 24 h, in a solution containing 85 ml of 2% 
paraformaldehyde and 15 ml of saturated picric acid per 100 ml of fixative. After 
washing several times with PBS containing 15% sucrose and 0.1% sodium 
azide, brains were processed for cryostat sectioning. Cryostat coronal sections 
(20 μm thick, Bregma 0.38) were permeabilized with 1% Triton X-100 in PBS for 
10 min at room temperature and then pretreated with blocking solution (10% 
bovine serum in PBS), for 1 h at room temperature. Incubation with primary 
antibody anti-Nrf2 (ab31163; Abcam) was performed overnight at 4°C. After 
extensive rinsing in PBS, the sections were incubated with FITC-conjugated 
goat anti-rabbit IgG (Alexa Fluor 488 A11008; ThermoScientific) and Hoechst, 
for 1 h at room temperature. Finally, sections were washed with PBS, mounted 
in fluorescent mounting medium observed under an Axioskop microscope (Carl 
Zeiss) with an attached Leica DFC490 camera, and photographed using Image 
Manager 50 software (Leica Microsystems, Inc.). 
 
 
 
 
 
 
Table 2 – List of primary antibodies used in the Western blot assays. 
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4. Statistical Analysis 
 
Data comparisons were conducted with one-way analysis of variance 
(ANOVA) followed by Tukey post hoc test. Differences between wild type and 
GSTP KO groups were analyzed by two-way ANOVA with Bonferroni post hoc. 
Analysis and graphical presentation were performed using GraphPad Prism 
software version 5 (GraphPad Software, Inc., San Diego, CA, USA). Results are 
presented as mean ± standard error of the mean (SEM). 
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III. RESULTS 
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1. The expression levels of mediators of the UPR pathways are altered 
in GSTP KO mice  
 
Even though recent studies show that ER stress may trigger ROS 
production and redox deviation in the ER, the precise mechanisms of interplay 
between oxidative stress and ER stress in the dopaminergic neurons have been 
sparsely described and whether ER stress plays a role in oxidative stress and 
anti-oxidant elicited neuronal response is currently unknown. 
In this work we started by analyzing the protein expression levels of the 
three main mediators of the UPR, ATF6α, IRE1α and PERK in mice brain 
samples under MPTP-induced oxidative stress and/or treated with the chemical 
chaperone TUDCA. Moreover, we also wanted to look for differences between 
the expression of these UPR mediators in both wt and GSTP KO mice brain. In 
fact, GSTP is an enzyme actively involved in the response to oxidative stress 
and we have already shown that it plays a role in the context of MPTP-induced 
lesions (Castro-Caldas et al., 2012). To assess the effects of Gstp1 and Gstp2 
genes deletion, and MPTP and/or TUDCA treatment in the expression levels of 
the three UPR branches, Western blot assays for wt and GSTP KO cortex 
samples were conducted.  
Results from Figure 5 show that in the GSTP KO mice cortex ATF6α 
protein levels are significantly reduced when compared to their wt counterparts 
in all of the conditions studied, except for control samples and in samples from 
mice treated with TUDCA and sacrificed 3 h after MPTP administration. 
Although we did not observe any effect of MPTP treatment on the expression 
levels of ATF6α in wt mice, when GSTP KO mice were treated with MPTP, the 
expression levels of ATF6α were significantly decreased. In order to evaluate 
the putative neuroprotective effects of TUDCA, a group of animals was treated 
with TUDCA. Similarly to what happened in MPTP-treated wt mice, TUDCA 
administration for three consecutive days had no effect in the expression levels 
of ATF6α. However, TUDCA led to a decrease in ATF6α expression levels in 
GSTP KO mice. Considering the wt mice, pre-treatment with TUDCA for three 
consecutive days prior to administration of MPTP for 6 h increased the 
expression levels of ATF6α. In the case of GSTP KO mice, the same treatment 
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schedule with TUDCA and MPTP decreased ATF6α expression levels at the 3 h 
time-point, when compared to the expression levels observed in control 
samples. 
Concerning the phosphorylated levels of PERK (p-PERK), we observed a 
decrease in the levels of this protein in the control samples of GSTP KO mice 
when compared to the corresponding wt control samples (Fig. 6). Treatment 
with MPTP resulted in different outcomes; it induced a significant decrease in 
the levels of p-PERK in wt mice, while it did not produce any change in GSTP 
KO mice. In the samples obtained from mice treated with TUDCA we observed 
a decrease in p-PERK levels in wt mice when compared to the corresponding 
controls. Furthermore, pre-treatment with TUDCA followed by a single MPTP 
administration for 3 or 6 h increased the expression levels of p-PERK in the wt 
mice, attaining the highest levels 6 h after MPTP administration, when 
compared to the control samples. Regarding the GSTP KO mice, pre-treatment 
with TUDCA had no significant effect at the 3 h time-point but induced a 
significant increase in p-PERK levels at the 6 h time point, when compared to 
the respective control samples. 
In the case of IRE1α, there is a significant increase in the expression 
levels of this ER stress mediator in the GSTP KO control samples when 
compared to the wt (Fig. 7). Curiously, the MPTP and TUDCA treatment had no 
significant effect on the expression levels of IRE1α in wt mice, but led to a 
significant decrease in the expression of IRE1α in GSTP KO mice. This 
decrease in IREα expression was also observed in GSTP KO mice pre-treated 
with TUDCA and sacrificed after MPTP administration. In fact, there was a 
significant decrease in IRE1α protein expression when compared to control 
samples that was similar at both 3 h and 6 h time-points. In wt samples, 
however, pre-treatment with TUDCA had a different effect; an increase in the 
expression levels of IRE1α was observed at the 6 h time-point in comparison 
with control samples and no significant changes were seen at the 3 h time-point 
 
 
. 
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Figure 5 - ATF6α expression levels in the brain cortex in response to treatment with TUDCA, MPTP or 
TUDCA + MPTP. C57/BL6 wild type and GSTP KO mice were i.p. injected with saline (control, C), 
TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h (T+M 3h) or 6h (T+M 
6h) after MPTP administration. (A) ATF6α levels were determined by Western blot analysis, using a 
mouse anti-ATF6 antibody. Analysis of β-actin was done in parallel as a loading control. The 
immunoblots shown are representative of three independent experiments. (B) The ATF6α levels in wt 
control samples were arbitrarily set as 1 and the relative levels in MPTP, TUDCA and TUDCA + MPTP 
samples were calculated and plotted as a fold induction over control. Data shown are mean ± SEM of 
three independent experiments. Statistical comparisons were performed using one-way ANOVA with 
Tukey post-hoc test and two-way ANOVA with Bonferroni post-hoc test where # p < 0.05 relative to wild 
type control; δ p < 0.05; δδ p < 0.01 relative to GSTP KO control; β p < 0.05 relative to TUDCA GSTP 
KO;  ** p < 0.01; *** p < 0.001 wild-type vs. corresponding GSTP KO. 
 
A 
B 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – p-PERK expression levels in the brain cortex in response to treatment with TUDCA, MPTP 
or TUDCA + MPTP. C57/BL6 wild type and GSTP KO mice were i.p. injected with saline (control, C), 
TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h (T+M 3h) or 6h (T+M 
6h) after MPTP administration. (A) p-PERK levels were determined by Western blot analysis, using a 
rabbit anti-p-PERK antibody. Analysis of PERK was done in parallel as a loading control. The 
immunoblots shown are representative of three independent experiments. (B) The p-PERK levels in wt 
control samples were arbitrarily set as 1 and the relative levels in MPTP, TUDCA and TUDCA + MPTP 
samples were calculated and plotted as a fold induction over control. Data shown are mean ± SEM of 
three independent experiments. Statistical comparisons were performed using one-way ANOVA with 
Tukey post-hoc test and two-way ANOVA with Bonferroni post-hoc test where ### p < 0.001 relative to 
wild type control; ; δδδ p< 0.001 relative to GSTP KO Control; ; ααα p < 0.001 relative to TUDCA wild 
type; βββ p < 0.001 relative to TUDCA GSTP KO; ** p < 0.01; *** p < 0.001 wild-type vs. corresponding 
GSTP KO. 
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Figure 7 – IRE1α expression levels in the brain cortex in response to treatment with TUDCA, 
MPTP or TUDCA + MPTP. C57/BL6 wild type and GSTP KO mice were i.p. injected with saline 
(control, C), TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h 
(T+M 3h) or 6h (T+M 6h) after MPTP administration. (A) IRE1α levels were determined by 
Western blot analysis, using a rabbit anti-IRE1α antibody. Analysis of β-actin was done in 
parallel as a loading control. The immunoblots shown are representative of three independent 
experiments. (B) The IRE1α levels in wt control samples were arbitrarily set as 1 and the 
relative levels in MPTP, TUDCA and TUDCA + MPTP samples were calculated and plotted as a 
fold induction over control. Data shown are mean ± SEM of three independent experiments. 
Statistical comparisons were performed using one-way ANOVA with Tukey post-hoc test and 
two-way ANOVA with Bonferroni post-hoc test where # p < 0.05 relative to wild type control; δδ 
p < 0.01; δδδ p< 0.001 relative to GSTP KO Control; α p < 0.05 relative to TUDCA wild type; β 
p < 0.05 relative to TUDCA GSTP KO; * p < 0.05; *** p < 0.001 wild-type vs. corresponding 
GSTP KO. 
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2. The expression levels of downstream effectors of the UPR 
pathways are altered in GSTP KO mice  
 
After measuring the expression levels of the three mediators of the UPR, 
we sought to analyze the expression levels of the downstream effectors of 
these pathways. Even though changes were observed in the protein expression 
levels of ATF6α, IRE1α and PERK, this does not necessarily mean that these 
pathways are activated. By analyzing the expression levels of p-eIF2α, a 
transcription factor phosphorylated by PERK, and the expression levels of 
CHOP, a transcription factor modulated by both the PERK and ATF6α branches 
of the UPR, we can perceive if the UPR mediators are indeed activating its 
respective effectors. With this purpose Western blot assays for wt and GSTP 
KO cortex samples were conducted to assess the protein expression levels of 
p-eIF2α and CHOP.  
In the case of p-eIF2α, (Fig. 8), the only significant changes were seen in 
GSTP KO mice treated with TUDCA for three consecutive days followed by 
single MPTP administration and sacrificed 6 hours after (T+M 6h), which 
showed an increase of expression when compared to their corresponding 
control samples. This result is similar to the previously described for p-PERK 
expression levels in the same analyzed samples. We also observed that in the 
wt and GSTP KO mice treated with TUDCA for three consecutive days the p-
eIF2α expression levels were significantly different, although no significant 
changes were detected when comparing with the respective control samples. 
 Regarding the expression levels of CHOP, we found no significant 
changes in the expression levels of this protein. We observed that in the wt and 
GSTP KO mice pre-treated with TUDCA and sacrificed after 6 h of MPTP 
administration the CHOP expression levels are significantly different but these 
values show no significant changes when comparing with the control samples 
(Fig. 9). 
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Figure 8 – p-eIF2α expression levels in the brain cortex in response to treatment with TUDCA, 
MPTP or TUDCA + MPTP. C57/BL6 wild type and GSTP KO mice were i.p. injected with saline 
(control, C), TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h 
(T+M 3h) or 6h (T+M 6h) after MPTP administration. (A) p-eIF2α levels were determined by 
Western blot analysis, using a rabbit anti-p-eIF2α antibody. Analysis of eIF2α was done in 
parallel as a loading control. The immunoblots shown are representative of three independent 
experiments. (B) The p-eIF2α levels in wt control samples were arbitrarily set as 1 and the 
relative levels in MPTP, TUDCA and TUDCA + MPTP samples were calculated and plotted as a 
fold induction over control. Data shown are mean ± SEM of three independent experiments. 
Statistical comparisons were performed using one-way ANOVA with Tukey post-hoc test and 
two-way ANOVA with Bonferroni post-hoc test where δ p< 0.05 relative to GSTP KO Control; 
ββ p < 0.01 relative to TUDCA GSTP KO; ** p < 0.01 wild-type vs. corresponding GSTP KO. 
GSTP KO; * p < 0.05; *** p < 0.001 wild-type vs. corresponding GSTP KO. 
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Figure 9 – CHOP expression levels mice cortex in response to treatment with TUDCA, MPTP 
or TUDCA + MPTP. C57/BL6 wild type and GSTP KO mice were i.p. injected with saline 
(control, C), TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h 
(T+M 3h) or 6h (T+M 6h) after MPTP administration. (A) CHOP levels were determined by 
Western blot analysis, using a rabbit anti-CHOP antibody. Analysis of β-actin was done in 
parallel as a loading control. The immunoblots shown are representative of three independent 
experiments. (B) The CHOP levels in wt control samples were arbitrarily set as 1 and the 
relative levels in MPTP, TUDCA and TUDCA + MPTP samples were calculated and plotted as a 
fold induction over control. Data shown are mean ± SEM of three independent experiments. 
Statistical comparisons were performed using one-way ANOVA with Tukey post-hoc test and 
two-way ANOVA with Bonferroni post-hoc test where α p < 0.05 relative to TUDCA wild type; β 
p < 0.05 relative to TUDCA GSTP KO; * p< 0.05 wild-type vs. corresponding GSTP KO. 
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3. Nrf2 expression levels are increased in wild type mice treated with 
MPTP 
 
The trigger for dysfunctional protein metabolism, in sporadic PD, may be 
oxidative stress through damage caused by ROS. One potential defence 
against the toxicity of ROS is the up-regulation of phase II detoxification 
enzymes, namely GSTP, by the Nrf2 transcription factor. Moreover, this 
transcription factor can also be activated through a pathway dependent of the 
UPR mediator PERK. Furthermore, preliminary results from our group have 
shown that MPTP-induced dopaminergic neuronal degeneration is an earlier 
event when comparing GSTP null versus wt mice, suggestive of a protective 
role for GSTP (Castro-Caldas et al., 2012).  
So afterwards we evaluated the Nrf2 protein levels in the cortex of both 
wt and GSTP KO mice by Western blot assay using a specific antibody.  
No significant differences were observed in the expression levels of Nrf2 
between wt and GSTP KO samples, except for the MPTP treatment (Fig. 10). In 
fact, treatment with MPTP results in increased expression levels of Nrf2 in the 
wt mice cortex samples.  
To further analyze the expression of Nrf2 in the experimental conditions 
already described and in order to evaluate its sub-cellular distribution in the 
mice brain cortex, immunohistochemistry assays were conducted using coronal 
sections of wt mice brain (Bregma 0.38). Results presented in Figure 11 (panel 
c) show that treatment with MPTP promotes the nuclear translocation of Nrf2 as 
demonstrated by the co-localization of the green fluorescence for Nrf2 antibody 
with the blue fluorescence for the nuclear marker, Hoechst. As shown in Figure 
11 (panel b), TUDCA treatment results in an increase in total Nrf2 levels which 
appears to be widespread throughout the cell (Fig.11 – panel b, insert). We also 
observed that Nrf2 expression is also increased when MPTP was administered 
following TUDCA for 3 consecutive days, with higher levels detected at the 3 h 
time point rather than the 6 h time point (Fig. 11- e and 11- d, respectively).  
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Figure 10 – Nrf2 expression levels in the brain cortex in response to treatment with TUDCA, 
MPTP or TUDCA + MPTP. C57/BL6 wild type and GSTP KO mice were i.p. injected with saline 
(control, C), TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h 
(T+M 3h) or 6h (T+M 6h) after MPTP administration. (A) Nrf2 levels were determined by 
Western blot analysis, using a mouse anti-Nrf2 antibody. Analysis of β-actin was done in 
parallel as a loading control. The immunoblots shown are representative of three independent 
experiments. (B) The Nrf2 levels in wt control samples were arbitrarily set as 1 and the relative 
levels in MPTP, TUDCA and TUDCA + MPTP samples were calculated and plotted as a fold 
induction over control. Data shown are mean ± SEM of three independent experiments. 
Statistical comparisons were performed using one-way ANOVA with Tukey post-hoc test and 
two-way ANOVA with Bonferroni post-hoc test where # p < 0.05 relative to wild type control; * p 
< 0.05; wild-type vs. corresponding GSTP KO. 
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Figure 11 – Nrf2 sub-cellular distribution in the brain cortex of C57/BL6 wild type mice in 
response to treatment with TUDCA, MPTP or TUDCA + MPTP. Mice were i.p. injected with saline 
(control, C), TUDCA (T; 50 mg/kg), MPTP (M; 40 mg/kg) or TUDCA + MPTP and sacrificed 3h 
(T+M 3h) or 6h (T+M 6h) after MPTP administration. Coronal sections at the level of the cerebral 
cortex (Bregma 0.38) from C57BL/6 wild-type mice were immune stained for Nrf2 protein (green). 
Hoechst (blue) was used as nuclear marker. Representative microphotographs from saline (a and 
a1), TUDCA (b and b1), MPTP (c and c1) and T+M 3h (d) or T+M 6h (e) are shown. Scale bar 
=100 µm; insert = 100 µm 
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IV. DISCUSSION 
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In this work we aimed to evaluate the expression levels of ER stress 
markers in C57/BL6 wt and GSTP KO mice brain using a sub-acute MPTP 
model of PD. Throughout this project both wt and Gstp null mice were used in 
order to clarify the potentially neuroprotective role of the GST isoform pi, GSTP, 
by studying ER stress responses in the context of MPTP-induced brain lesions. 
Moreover, in parallel, TUDCA was used as a chemical chaperone already 
described as an ER stress reducer.  
In the following section we will discuss our results focusing on: (a) the 
effects of MPTP administration, (b) the effects of GSTP null mouse genotype, 
and (c) the effects of TUDCA treatment. 
Although MPTP has been described as having a regional specificity 
towards dopaminergic neurons in the striatum (Dauer and Przedborski, 2003), 
there are also reports of DA reduction in the cortex, as well as biochemical 
alterations in all catecholaminergic neurons resulting from MPTP neurotoxicity 
(Hallman et al., 1984; Wallace et al., 1984).  
Concerning the UPR modulation, it has been shown that ATF6α and 
PERK/eIF2α/ATF4 pathways are activated in mice nigrostriatal dopaminergic 
neurons upon treatment with MPTP (Hashida et al., 2012). However, our results 
show no significant differences in ATF6α expression levels in the cortex of wt 
mice following MPTP administration and p-PERK expression levels are actually 
decreased when compared to controls. We also found that in response to 
MPTP treatment, the protein levels of CHOP, a downstream effector of ATF6α, 
are not significantly different from the controls. These results are in 
contradiction with what was previously described. In fact, it has been shown that 
MPTP induces CHOP expression both in vitro (Holtz and O’Malley, 2003) and in 
vivo (Silva et al., 2005) in the SN of mice treated with this neurotoxin. Our work 
focused on the effects of MPTP in the brain cortex and, to our knowledge, there 
are not any reports concerning CHOP expression in this brain region in the 
context of MPTP lesions. Given the fact that MPTP may have a more 
pronounced and specific effect in the SN, it is possible that in the cortex it may 
trigger a mild ER stress response, in which sub-lethal levels of ER stress 
selectively engage adaptive UPR signaling events, a response that may involve 
the expression of XBP1s but not CHOP (Fouillet et al., 2012).  
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Looking at the IRE1α branch of the UPR, our results suggest that this 
pathway may not be involved in the ER-stress response to MPTP exposure in 
the cortex of wt mice, as IRE1α expression levels in the neurotoxin-treated mice 
are not increased when compared to their controls. These results are in 
accordance with previously described work, showing that IRE1α is not activated 
in the event of MPTP-induced lesions (Sado et al., 2009). 
In the light of these results, we can speculate that in this model of single 
acute MPTP administration there is no increase in ER stress markers. This may 
be explained through several reasons: the first one, as previously mentioned, is 
that in this model, MPTP may only trigger a mild ER stress response. Secondly, 
the time-point used for MPTP administration (mice were sacrificed 6 h after 
single MPTP administration) may not be the most appropriate. Previously our 
group has reported that 6 h after MPTP administration p-JNK control levels are 
restored (Castro-Caldas et al., 2012). But since we are looking at ER stress 
markers, this time-point may not be adequate. Thirdly, the number of samples 
analyzed was not ideal and some of these samples present a high variability, 
which makes definite results harder to achieve.  
Further studies are needed at different time-points following MPTP 
administration and a larger number of samples should be analyzed. 
Our Western blot results also revealed that Nrf2 expression is increased 
in MPTP-treated wt mice when compared to controls. In parallel, higher nuclear 
translocation was detected in the immunohistochemistry assay, suggestive of 
an activation of Nrf2 in the cortex of MPTP-treated mice. These results are in 
accordance to the literature, as Nrf2 regulates the adaptive response to 
oxidants and electrophiles (Ma, 2008). Moreover, our results are also supported 
by reports using the MPTP mouse model in which the knockout of Nrf2 in mice 
increased the sensitivity to MPTP (Chen et al., 2009). Also, others have shown 
that the knockout of Nrf2 in mice increases the susceptibility to a broad range of 
chemical toxicity and disease conditions associated with oxidative pathology 
(Chan et al., 2001; Motohashi and Yamamoto, 2004; Walters et al., 2008). 
According to our results, it seems that Nrf2 is actively involved in the response 
to oxidative stress and in the response to MPTP-induced oxidative stress in 
particular, probably contributing to cell survival and redox homeostasis. 
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We also sought to evaluate the potential neuroprotective effect of GSTP 
in the context of ER stress induced by MPTP-induced oxidative stress. The 
most interesting results obtained concern the AFT6α and IRE1α proteins. The 
protein expression analyses of ATF6α showed that there is a decrease in the 
expression levels of this protein in GSTP KO mice when compared to their wt 
counterparts in most of the conditions studied. We may speculate that in the 
absence of GSTP, ATF6α is down-regulated. This hypothesis may be explained 
by a possible up-regulation of ATF2, a transcription factor that can bind to 
GSTP through protein-protein interactions, which results in its inhibition 
(Thévenin et al., 2011). ATF2 has been shown to be connected in a negatively 
acting feedback loop to the MAPK p38 through the activation of p38-specific 
phosphatases (Breitwieser et al., 2007). The p38 kinase is an enzyme that 
promotes the phosphorylation of ATF6α in the event of ER stress, inducing its 
transcriptional activity and enhancing ATF6α ability to transactivate certain 
genes (Thuerauf et al., 1998; Luo and Lee, 2002; Egawa et al., 2011). It would 
have been interesting to analyze if the deletion of Gstp1/2 results in increased 
ATF2 expression levels, which in turn would negatively regulate p38, 
decreasing its expression, leading to a decreased activation of ATF6α.  
Regarding the IRE1α pathway of the UPR, Gstp1/2 deletion has the 
opposite effect when compared with ATF6α. IRE1α expression levels in control 
and MPTP-treated samples are higher than their wt counterparts, suggesting an 
up-regulation of this pathway. One possible explanation for this putative up-
regulation may be trough an increased TRAF2 activation. It has been shown 
that over-expression of GSTP attenuates TRAF2-ASK1 auto-phosphorylation by 
suppressing the interaction between TRAF2 and ASK1, and silencing of GSTP 
results in an increase in TRAF2-ASK1 association (Wu et al., 2006). It has also 
been shown that the cytoplasmic domain of IRE1α bounds TRAF2, which in turn 
activates the JNK pathway (Urano et al., 2000). We may speculate that TRAF2-
ASK1 increased association due to Gstp1/2 deletion may prompt an increase in 
IRE1α expression levels due to an unknown crosstalk mechanism, meaning that 
GSTP probably may regulate IRE1α expression through an indirect interaction 
with this UPR mediator.  
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In conclusion, we speculate that GSTP may have a neuroprotective 
effect concerning the ATF6α pathway of the UPR, as GSTP KO mice present a 
decreased expression of this protein. In the case of IRE1α, we speculate that 
overexpression of GSTP may result in a decreased expression of this protein. 
In this work we also wanted to evaluate the possible neuroprotective role 
of GSTP using the MPTP mouse model of PD. The most prominent effect of 
Gstp1/2 deletion was observed in the MPTP-treated samples, in which Nrf2 
expression levels have a significant decrease when compared to their wt 
counterparts. This may result in a deficient response to oxidative stress caused 
by MPTP, which may prompt an increase in apoptosis. It has been shown that 
Keap1, which physically interacts with Nrf2 and promotes its ubiquitination 
driving it for proteosomal degradation (Kobayashi et al., 2004), is modified by S-
glutathionylation. This post-translational modification might result in the 
dissociation of Keap1 from Nrf2, promoting Nrf2 activation and the consequent 
synthesis of proteins involved in the antioxidant response (Zhang et al., 2010). 
Previous reports have shown that GSTP is actively involved in S-
glutathionylation following nitrosative and oxidative stress (Townsend et al., 
2009). Even though GSTP KO mice samples do not present significant changes 
from their respective controls, the results point towards a tendency of lower 
expression levels of Nrf2 in GSTP KO mice samples treated with MPTP when 
comparing to their respective controls. We may speculate that GSTP may be 
involved in Keap1 S-glutathionylation and in the absence of GSTP reactive 
Keap1 cysteines residues are not glutathionylated, which may result in 
increased ubiquitination of Nrf2 and consequent proteosomal degradation.  
The final goal of this work was to assess the potential therapeutic value 
of TUDCA both in the context of MPTP-induced oxidative stress and 
consequent ER stress. Previously, our group has reported that TUDCA can 
prevent MPTP-induced cell death in dopaminergic neurons (Castro-Caldas et 
al., 2012).  
Our results regarding the analysis of ATF6α protein expression show that 
TUDCA treatment had no significant changes the expression of this ER stress 
mediator in the brain cortex of wt mice while decreasing its expression in 
TUDCA-treated GSTP KO mice when compared to control samples. The results 
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for wt mice are supported by reports that show that TUDCA does not have any 
effect in the expression levels of ATF6α (Hua et al., 2010). When TUDCA was 
administered before MPTP exposure, an increase of expression is seen at the 6 
h time-point. However, in GSTP KO mice, pre-treatment with TUDCA promotes 
a decrease in the expression of ATF6α at the 3 h time-point while showing no 
significant changes at the 6 h time-point when comparing to control samples, 
suggesting that Gstp1/2 deletion may result in a more prominent decrease in 
the expression levels of ATF6α. We speculate that the TUDCA pre-treatment 
coupled with inhibition of GSTP may have a more significant effect in 
modulating ATF6α expression levels at earlier stages of MPTP administration. 
Concerning the ATF6α downstream mediator CHOP, even though we 
could not detect any significant difference, in samples from TUDCA-treated 
mice there is a tendency to a reduction in CHOP levels when comparing to their 
respective controls, an effect that has been previously described (Malo et al., 
2010; Gao et al., 2012).  
In the case of IRE1α, treatment with TUDCA had no significant effect in 
the expression levels of this protein in the cortex of wt mice, while showing a 
significant  
decrease in GSTP KO mice. This data is in contrast to previous reports that 
show that TUDCA promotes the suppression of IRE1α and consequent JNK 
activation (Ozcan et al., 2006). Furthermore, pre-treatment with TUDCA 
appears to have the opposite effect on wt mice, showing an increase of the 
expression levels of IRE1α at the 6 h time point. This could mean that in the 
event of MPTP-induced neurotoxicity, TUDCA promotes the increase of IRE1α 
expression levels as a compensatory mechanism, which then may induce 
expression of chaperones and ERAD components, unloading ER burden. 
Looking at the PERK pathway, treatment with TUDCA reduced p-PERK 
expression levels in wt mice when compared to the respective controls, an 
effect that has been previously described (Ozcan et al., 2006). However, other 
reports have shown that TUDCA promotes the increase of p-PERK expression 
levels (Seyhun et al., 2011; Gani et al., 2015) so it is not exactly clear yet how 
TUDCA exerts its effects in the modulation of p-PERK expression levels. Pre-
treatment with TUDCA increased the phosphorylation levels of PERK in wt mice 
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more prominently at the 6 h time point, suggesting that in the event of MPTP-
induced neurotoxicity, TUDCA may promote the expression of p-PERK, with a 
more prominent effect in later stages following the insult. 
Although speculative, we may conclude that TUDCA modulates ER 
stress in early stages of MPTP-induced oxidative stress while promoting the 
expression of mediators of the UPR pathways in later stages. 
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